Helps diagnose adrenal insufficiency. Sold as Metopirone. Every FDA application for this active ingredient.
As of Nov 13, 2026, FDA lists 1 application for Metyrapone (sold as Metopirone), first approved Dec 4, 1961, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Metopirone | Part D | $1.6M | +20% | 46 |
| Sleep Loss and Circadian Misalignment - Mechanisms of Insulin ResistanceShift Work Schedule, Circadian Rhythm · Washington State University | Phase 4 | Recruiting | Mar 27, 2026 |
| Metyrapone Versus Osilodrostat in Patients With Metabolic Autonomous Cortisol Secretion (MACS)Mild Autonomous Cortisol Secretion (MACS) · Laikο General Hospital, Athens | Phase 4 | Recruiting | Dec 5, 2025 |
| Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACSMild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS) · Mayo Clinic | Phase 2 | Recruiting | Aug 22, 2025 |
| Effect of Metyrapone on Cardiovascular Risk Factors in Patients With Adrenal Incidentalomas and Cushing's SyndromeAdrenal Incidentalomas, Cushing Syndrome · IRCCS Azienda Ospedaliero-Universitaria di Bologna | Phase 4 | Recruiting | Jan 30, 2025 |
| Metyrapone for Mild Autonomous Cortisol Secretion (MACS)Autonomous Cortisol Secretion, Mild Autonomous Cortisol Secretion (MACS) · Mayo Clinic | Phase 2 | Active, not recruiting | Oct 30, 2023 |
| Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.Adrenocortical Carcinoma · Maria Sklodowska-Curie National Research Institute of Oncology | Phase 2 | Active, not recruiting | Oct 3, 2022 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Dec 4, 1961 | MetopironeNDA 12911 · New molecular entity | Esteve | 24 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA